linjc16/ctgov huggingface dataset:
Surveillance Monitoring on General Wards

Study Overview
=================
Brief Summary
-----------------
This is a study to determine if surveillance monitoring of general ward patients can reduce cardio-pulmonary arrest while maintaining an acceptable false alarms rate for nursing workload.

Detailed Description
-----------------
The investigators placed a wired monitoring system (pulse oximetry, heart rate and respiratory rate) on every patient who arrived on a subject general post surgical ward who assented to wear the system. this was the Masimo PSNET system using the Radical 87 monitor and an acoustic respiratory sensor along with a Masimo pulse oximetry probe. Patients were monitored for a minimum of 48 hrs. Heart Rate (HR) parameters were set between 45-130, Respiratory rate was set between 6-20 and pulse oximetrry was 85-100%. Nurses documented in the Electronic Medical Record (EMR) any alarms they responded to as to whether they were false (vital sign not out of range when rechecked) or true and what the response was. Responses ranged from nurse managed to notification of primary service to Rapid Response Activation to Code team activation as well as transfer to a higher level of care (operating room or Intensive Care Unit (ICU)/IMC. Patient and Nursing satisfaction surveys were collected.

Official Title
-----------------
Surveillance Monitoring on General Wards

Conditions
-----------------
Cardiac Arrest

Intervention / Treatment
-----------------
* Device: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all post-surgical patients admitted to a post-operative general hospital ward Exclusion Criteria: inability to understand English or provide verbal consent for data analysis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: No intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| positive predictive value (PPV) | The PPV of the wired monitoring system (pulse oximetry, heart rate and respiratory rate) will be determined based on change in vital signs (HR<45 or >130, RR<6 or >20 and pulse oximetry <85) indicating clinical deterioration | 6 months |
Effects of Stress on Glucose Tolerance During Pregnancy

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to investigate the effect of stress on glucose tolerance during pregnancy. The main objectives of the study are to investigate if various measures of stress (stressful life events, the perceived level of stress and the cortisol or copeptin concentrations) differ between pregnant women with and without gestational diabetes during the end of the second/beginning of the third trimester when presenting for their routine glucose tolerance testing. Secondary objectives are the link between these different stress measures and the routinely measured fasting and stimulated glucose levels during the oral glucose tolerance test.

Detailed Description
-----------------
Hypotheses in this study, 3 primary hypotheses will be tested. Women with gestational diabetes have more life events compared to pregnant women without gestational diabetes. Women with gestational diabetes have higher perceived level of stress and anxiety compared to pregnant women without gestational diabetes. Women with gestational diabetes have higher measures of cortisol levels in the saliva and in the nailfolds and higher plasma copeptin levels compared to pregnant women without gestational diabetes. Secondary objectives: 1. To test the link between these stress measures and the fasting and stimulated glucose levels during the oral glucose tolerance test.

Official Title
-----------------
Effects of Stress on Glucose Tolerance During Pregnancy

Conditions
-----------------
Stress, Pregnancy, Gestational Diabetes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All pregnant women who are undergoing a 75 g oral glucose tolerance test at the Maternité of CHUV at 24-30 weeks of gestation between October 2012 and April 2013 Exclusion Criteria: Pregnant woman who has the use if medications that influence either the cortisol and /or the glucose levels Pregnant woman who has the inability to fill out the questionnaires with assistance
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women with gestational diabetes<br>Women with gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing | |
| Women without gestational diabetes<br>Women without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Markers of stress | stress (stressful life events, the perceived level of stress and the cortisol or copeptin concentrations) | At assessment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pregnancy, Stress, Anxiety, Cortisol, Copeptin, Gestational diabetes
Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue Diseases in Egyptian Patients

Study Overview
=================
Brief Summary
-----------------
Measuring the incidence and prevalence of PAH in Egyptian patients with different types of MCD Determination of survival & the risk factors of mortality.

Detailed Description
-----------------
PH is defined as a mean pulmonary artery pressure greater than 25 mmHg. PAH can be assessed by different means, however right heart catheterization (RHC) is the gold standard diagnostic method . Among the different subgroups of pulmonary arterial hypertension (PAH), those associated with connective tissue diseases (CTDs) are a specific entity with distinct hemodynamic and prognostic features reflecting the importance of a rheumatological assessment in PAH, especially with the unfavorable prognostic impact in these patients. Compared to patients with idiopathic PAH, patients with CTD-associated PAH have a higher mortality and a lower walking distance on the 6-minute walk test, higher levels of B-type natriuretic peptide, worse right ventricular function, more left-sided heart dysfunction, lower lung function, and more pericardial disease. That's why, PAH screening is routinely performed in systemic sclerosis (SSc) and in other CTDs and also, as suggested by international guidelines, it is important to rule out CTDs in patients with PAH, because patients diagnosed as idiopathic PAH (iPAH) may have an associated CTD previously unrecognized. Although the similarities in pathogenesis of PAH in CTD such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), and mixed connective tissue disease (MCTD), there are variabilities in outcomes in patients with CTD-associated PAH.

Official Title
-----------------
Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue in Egyptian Patients ( Single Center Study)

Conditions
-----------------
Connective Tissue Diseases, Pulmonary Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients diagnosed as connective tissue diseases fulfilling ACR criteria will be recruited Exclusion Criteria: non -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence | Pulmonary hypertension | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival |  | 1 year |
Factors and Characteristics of Heart Rate Variability in Runners

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to describe the variation characteristics and factors of the heart rate variability during long-distance running.

Detailed Description
-----------------
Heart rate variability is recognized as the indicator to measure the autonomic nerve activity. By monitoring the heart rate variability of runners during long-distance running, we could monitor the status of the runners' cardiovascular system and predict the exercise risk of runners during long-distance running.

Official Title
-----------------
Factors and Characteristics of Heart Rate Variability During Long Distance Running

Conditions
-----------------
Heart Rate Variability, Sports Accident

Intervention / Treatment
-----------------
* Behavioral: a long-distance running (over 3 km)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People have below conditions could be included: age is 18-60 years. have normal ECG . agree to participate in the study. Exclusion Criteria: People have below conditions will be excluded: have known Congenital heart disease and rheumatic heart disease. have known Hypertension and cerebrovascular disease. have known Myocarditis and other heart diseases. have known Coronary artery disease and severe arrhythmia. have known Diabetes with high or low blood glucose. have a cold within two weeks before the study. have other diseases considered unsuitable for participants in this study. -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Healthy adults with regular exercise<br>Subjects will be asked to wear a small monitoring equipment before,during and after a long distance running (over 3 km). | Behavioral: a long-distance running (over 3 km)<br>* Complete a long distance running（over 3 km） within the specified time (30 minutes)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of heart rate variability | Subjects will be asked to wear a small monitoring equipment before,during and after a long distance running (over 3 km)， and complete the corresponding amount of exercise within a specified time during the test | up to 1 year |
Physical Activity, Hypertension, Diabetes, and Coronary Heart Disease

Study Overview
=================
Brief Summary
-----------------
To study the influences of physical activity on the incidence of hypertension, non-insulin-dependent diabetes (NIDDM), and coronary heart disease (CHD), taking into account the influences of other life-style elements such as body size, cigarette habit, alcohol consumption habits, and parental history of disease on these same chronic diseases.

Detailed Description
-----------------
BACKGROUND: Epidemiologic investigations of the influence of physical activity on the incidence of specific chronic diseases encounter problems of confounding or interaction with eating behavior, tobacco use, other social habits, and a host of personal characteristics. These influences of life styles on chronic diseases are not mutually exclusive, nor do they operate independently. Rather, they blend, amplifying or diminishing the effects of one another. DESIGN NARRATIVE: The study used data collected since 1960 as part of the College Alumni Health Study -- a cohort of 50,000 former students who attended Harvard College, 1916-1950, or the University of Pennsylvania, 1931-1940, and who reported by questionnaire on their health habits and health status in post-college years through 1988. Over 17,000 Harvard alumni have been followed from 1962 through 1988 for both non-fatal and fatal chronic diseases. These predictor (risk factors) and outcome (specific diseases) data were analyzed to test the hypothesis that different kinds and amounts (frequencies, intensities, durations, and constancies) of physical activity affect differently the incidence rates of hypertension, NIDDM, and CHD. Continuities and changes in specific life styles and chronic diseases have been measured continually through return-mail questionnaires in 1962, 1966, 1972, I977, and 1988. Cause-specific mortality has been monitored continuously over this span of time, 1962-1988. Using the data, the investigators computed relative and attributable risks of developing hypertension, NIDDM, and CHD that related to alumni patterns of physical activity, body size, alcohol consumption, cigarette use, and other personal characteristics and ways-of-living. In this discrete population, they searched for the relative importance of physical activity and other potential predictors in influencing the occurrence of these hypertensive-metabolic-atherosclerotic diseases.

Conditions
-----------------
Cardiovascular Diseases, Heart Diseases, Diabetes Mellitus, Coronary Disease, Hypertension, Diabetes Mellitus, Non-insulin Dependent

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Vitamin D and Staphylococcus Aureus in the Diabetes Study

Study Overview
=================
Brief Summary
-----------------
There are indications that the vitamin D status of an individual is related to susceptibility to staphylococcal infections. In the present study we will examine nasal colonisation rate in subjects participating in an ongoing vitamin D intervention study ( 20.000 IU cholecalciferol per week vs placebo) for the prevention of type 2 diabetes in subjects with impaired glucose tolerance.

Official Title
-----------------
Vitamin D and Staphylococcus Aureus in the Diabetes Study

Conditions
-----------------
Infection

Intervention / Treatment
-----------------
* Drug: cholecalciferol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: participant in an ongoing intervention study with vitamin D Exclusion Criteria: none specifically for this study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: cholecalciferol<br>cholecalciferol 20.000 IU per week | Drug: cholecalciferol<br>* 20.000 IU per week, oral<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| nasal staphylococcus colonisation |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
staphylococcus aureus, vitamin D
Human Anaplasmosis in Eastern France

Study Overview
=================
Brief Summary
-----------------
Anaplasmosis is a tick-borne transmitted infection. Its clinical expression include fever, cytopenia and hepatitis.This infection was initially described in United States. In Europe, its epidemiology is not well known. Some isolated cases have been diagnosed in several country, were the tick Ixodes ricinus is known to transmitted another infection :the Lyme borreliosis.The purpose of our study is to look systematically for Anaplasmosis, in patient living in Eastern France, and presenting with compatible clinical symptoms using a new diagnosis tool : PCR in blood samples. So we will have new data about epidemiology in our country and the clinical symptoms that are associated with Anaplasmosis.

Official Title
-----------------
Epidemiology and Clinical Presentation of Human Anaplasmosis in Eastern France

Conditions
-----------------
Anaplasmosis, Tick-borne Disease, Ehrlichia

Intervention / Treatment
-----------------
* Procedure: Blood sampling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with at least one of following symptoms : fever or muscular pain or articular pain or respiratory signs or neurological signs or meningitis or erythema occurring during the three weeks after a tick bite- Or patient with fever with at least one of following criteria : thrombocytopenia, leucopenia, hepatitis, without any other cause that can explain these abnormalities. Or patient with tick-borne encephalitis, or primary stage Lyme borreliosis Exclusion Criteria: children less that 10 years pregnancy patients with an other diagnosis that can explain clinical symptoms or biological abnormalities antibiotherapy with cyclins during the days before inclusion

Ages Eligible for Study
-----------------
Minimum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Anaplasma<br> | Procedure: Blood sampling<br>* Anaplasma diagnosis test : serology and PCR If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk factor, clinical and biological markers of infection for patients with Anaplasma antibody seroconversion |  | 6 weeks |
Safety Profile of Hydroxyethyl Starch

Study Overview
=================
Brief Summary
-----------------
The study is primarily aimed to collect further data on the safety of the investigational product in a large patient population when used in routine clinical practice in the Asian-Pacific region.

Official Title
-----------------
Evaluation on the Safety Profile of Hydroxyethyl Starch (HES) 130/0.42

Conditions
-----------------
Plasma Volume Replacement

Intervention / Treatment
-----------------
* Drug: Venofundin 6% / Tetraspan 6%


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: patients with ASA risk score ≤ III, non-emergency patients, i.e. elective surgery Exclusion: contraindications as listed for HES 130/0.42

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>hydroxyethyl starch (HES) 130/0.42 | Drug: Venofundin 6% / Tetraspan 6%<br>* Venofundin 6% / Tetraspan 6%<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of adverse drug reactions |  | up to 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in haemodynamics during surgery or intensive care unit stay |  | up to 48 hours |
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases

Study Overview
=================
Brief Summary
-----------------
This is a study to evaluate the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals combined measles-mumps-rubella varicella candidate vaccine given to healthy children in their second year of life.

Detailed Description
-----------------
Separate injections of the licensed Priorix (MMR vaccine) and Varilrix (chickenpox vaccine) serve as control.

Official Title
-----------------
Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life

Conditions
-----------------
Mumps, Varicella, Rubella, Measles

Intervention / Treatment
-----------------
* Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A male or female subject between 11-13 months of age (i.e. from 11 month birthday until the day before the 14 month birthday) at the time of the first vaccination. Exclusion Criteria: History of previous measles, mumps, rubella and/or varicella vaccination or disease, or known exposure to any of these diseases within 30 days prior to the start of the trial Planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination

Ages Eligible for Study
-----------------
Minimum Age: 11 Months
Maximum Age: 21 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: Measles, Mumps, Rubella and Chickenpox (live vaccine)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antibody levels after vaccination. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety of the study vaccines. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prophylaxis measles, mumps, rubella and chickenpox